0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TROP-2

TROP-2

Brief Information

Name:Tumor-associated calcium signal transducer 2
Target Synonym:Trophoblast Cell Surface Antigen 2,Tumor-associated calcium signal transducer 2,M1S1,TROP2,TACSTD2,Pancreatic carcinoma marker protein GA733-1,Tumor Associated Calcium Signal Transducer 2,GA733-1,Membrane Component, Chromosome 1, Surface Marker 1,Gastroin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

TR2-R52H3-ELISA
Rhesus macaque / Cynomolgus TROP-2, His TagRhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) ELISA bioactivity

Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

TR2-R52H3-MALS-HPLC
Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. ) MALS images

The purity of Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) was more than 85% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.

Bioactivity-ELISA
Rhesus macaque / Cynomolgus TROP-2, His TagRhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) ELISA bioactivity

Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Customer Reviews

Synonym Name

TACSTD2,GA733-1,M1S1,TROP2

Background

TROP-2 is a single-copy gene in human cells, and encodes a type-1 transmembrane glycoprotein which is over-expressed in various malignancies, also referred to as tumor associated calcium signal transducer 2 (TACSTD2), GA733-1 or M1S1. TROP-2 is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. Trop-1 and Trop-2 are homologous to serum IGF-II-binding proteins and appear as signal transducers. Thus, they likely represent novel cell-surface receptors and may play a role in regulating the growth of carcinoma cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sacituzumab govitecan IMMU-132; TROP-2-SN-38 Approved Immunomedics Inc Trodelvy United States Carcinoma, Transitional Cell Immunomedics Inc 2020-04-22 Glioblastoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Metastatic breast cancer; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Liver Failure; Ovarian Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
DAC-002 DAC-002; JS-108 Phase 1 Clinical Hangzhou Dac Biotech Co Ltd Solid tumours; Triple Negative Breast Neoplasms Details
BAT8003 BAT-8003 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Carcinoma, Transitional Cell Details
SKB-264 SKB-264 Phase 2 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
重组人源化抗Trop2单抗-SN38偶联物 Phase 1 Clinical Shanghai Shijian Biotechnology Co Ltd, Tot Biopharm Co Ltd Solid tumours Details
ESG-401 Phase 2 Clinical Shanghai Shijian Biotechnology Co Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms Details
Datopotamab deruxtecan DS-1062a; DS-1062; Dato-DXd Phase 3 Clinical Daiichi Sankyo Co Ltd Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop